Subtype
Testicular Non-Seminomatous Germ Cell Tumor
CI-CAN-00001570Explore in graph →
Non-malignant3 active trials
- NCIt
- C9313
Loading cancer entity…
Subtype
CI-CAN-00001570Explore in graph →
Clinical trials
10 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT00467051 |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials
| completed |
| Phase 2 |
| 20 |
| Children's Oncology GroupNETWORK |
| 4 |
| Aug 29, 2018 |
| clinicaltrials |